Citicoline in Ischemic Stroke

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT05154903

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT05154903
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Egypt (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT05154903. Randomized; no masking; primary purpose treatment. Start 2021-07-22 (actual); primary completion 2022-04-22 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Citicoline in Ischemic Stroke
Condition
Acute Ischemic Stroke
Intervention (Drug)
Citicoline 500 MG
Lead sponsor
Ain Shams University (class: other)
Collaborator
Kafrelsheikh University (class: other)

Record details

Record id
cardio:ct-nct05154903
Content hash
43423bc941aa9766c5d37c4737ff1dfb4b7bad709bfe375b2337ecd47c692d25